SCHEMBL2268353

SCHEMBL2268353

N[C@@H](C[C@@H]1CCNC1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.53
GABRA5 P31644 2/20 0.53
GABRB2 P47870 2/20 0.53
SLC6A12 P48065 2/20 0.53
SLC6A11 P48066 2/20 0.53
SLC6A13 Q9NSD5 2/20 0.53
GABRA1 P14867 1/20 0.53
GABRR1 P24046 1/20 0.53
GABRA4 P48169 1/20 0.53
CPN1 P15169 3/20 0.49
CPB2 Q96IY4 3/20 0.49
GRIN2D O15399 5/20 0.37
GRIN3B O60391 5/20 0.37
GRIN1 Q05586 5/20 0.37
GRIN2A Q12879 5/20 0.37
GRIN2B Q13224 5/20 0.37
GRIN2C Q14957 5/20 0.37
GRIN3A Q8TCU5 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2268358 1.00 SLC6A1 (0.53) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL25661085 1.00 SLC6A1 (0.53) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL1309969 0.89 CPN1 (0.62) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL1062937 0.89 CPN1 (0.62) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL25358028 0.89 CPN1 (0.58) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL2749798 0.89 CPN1 (0.58) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL160000 0.89 CPN1 (0.58) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL1800252 0.85 SLC6A1 (0.48) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL1800254 0.85 SLC6A1 (0.48) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL24740306 0.85 SLC6A1 (0.48) SLC6A1GABRA5GABRB2SLC6A12SLC6A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 SLC6A1 4799/4885GABRA5 4526/4885GABRB2 3818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.